{"id":3537,"date":"2025-04-05T18:37:32","date_gmt":"2025-04-05T15:37:32","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3537"},"modified":"2025-11-17T18:28:40","modified_gmt":"2025-11-17T15:28:40","slug":"mrna-duchenne-muscular-dystrophy-dmd-treatment","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/mrna-duchenne-muscular-dystrophy-dmd-treatment\/","title":{"rendered":"DMD Tedavisinde mRNA \u00c7al\u0131\u015fmalar\u0131: Gelecekteki Terap\u00f6tik Adaylar"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Duchenne Musk\u00fcler Distrofisi i\u00e7in FDA onayl\u0131 ekzon atlama terapileri ve gen terapisi, yeterli distrofin seviyeleri \u00fcretmedi\u011fi ve dolay\u0131s\u0131yla Duchenne Musk\u00fcler Distrofisi&#039;ni (DMD) tamamen ortadan kald\u0131rmad\u0131\u011f\u0131 bilinmektedir. Y\u0131llar boyunca DMD i\u00e7in tedavi se\u00e7enekleri s\u0131n\u0131rl\u0131yd\u0131, ancak mRNA teknolojisinin kullan\u0131m\u0131yla umut vadeden bir ara\u015ft\u0131rma alan\u0131 ortaya \u00e7\u0131kt\u0131. Bu \u00e7al\u0131\u015fmalar, DMD hastal\u0131\u011f\u0131 i\u00e7in tam uzunlukta ve normal distrofin \u00fcretimini sa\u011flayabilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Her ne kadar ekzon atlama tedavileri ve gen terapisi yak\u0131n zamanda ABD G\u0131da ve \u0130la\u00e7 Dairesi (FDA) taraf\u0131ndan onaylanm\u0131\u015f olsa da, bunlar\u0131n hi\u00e7birinin DMD&#039;yi tamamen iyile\u015ftirdi\u011fi d\u00fc\u015f\u00fcn\u00fclmemektedir ve miyofiber b\u00fct\u00fcnl\u00fc\u011f\u00fcn\u00fc geri kazand\u0131ran, kas rejeneratif kapasitesindeki kayb\u0131 tersine \u00e7eviren ve mitokondriyal i\u015flev bozuklu\u011funu ele alan y\u00f6ntemler yaratmaya y\u00f6nelik acil bir ihtiya\u00e7 devam etmektedir; bunlar\u0131n hi\u00e7biri mevcut tedaviler taraf\u0131ndan sunulmamaktad\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Yakla\u015f\u0131k 5.000 erkek yenido\u011fandan 1&#039;i, en ciddi kas dejenerasyonu hastal\u0131klar\u0131ndan biri olan DMD&#039;den etkilenir. X kromozomuyla ili\u015fkili distrofin genindeki mutasyonlar nedeniyle ortaya \u00e7\u0131kar. DMD&#039;li gen\u00e7 erkekler kademeli kas dejenerasyonu, iltihaplanma, fibroz ya\u015far ve sonunda kalp ve solunum yetmezli\u011finden \u00f6l\u00fcrler. (<a href=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2024\/09\/what-is-dmd-duchenne.jpg\" data-type=\"attachment\" data-id=\"3314\">Duchenne nedir?<\/a>)<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u0130\u00e7indekiler<\/h2><nav><ul><li><a href=\"#ongoing-m-rna-studies-for-dmd-treatment\">DMD Tedavisi \u0130\u00e7in mRNA \u00c7al\u0131\u015fmalar\u0131<\/a><ul><li><a href=\"#bobcat-m-rna\">Bobcat mRNA&#039;s\u0131 (Elixirgen Therapeutics)<\/a><\/li><li><a href=\"#auf-1-expression\">AUF1 mRNA Ba\u011flay\u0131c\u0131 Protein (Regerna Therapeutics)<\/a><\/li><li><a href=\"#dmd-anka-m-rna-study-in-turkiye\">DMD ANKA (T\u00fcrkiye&#039;de mRNA \u00c7al\u0131\u015fmas\u0131)<\/a><ul><li><a href=\"#key-findings-from-m-rna-study-in-turkiye\">T\u00fcrkiye&#039;deki mRNA \u00c7al\u0131\u015fmas\u0131ndan Elde Edilen Temel Bulgular<\/a><\/li><\/ul><\/li><\/ul><\/li><li><a href=\"#conclusion\">Sonu\u00e7<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"ongoing-m-rna-studies-for-dmd-treatment\">DMD Tedavisi \u0130\u00e7in mRNA \u00c7al\u0131\u015fmalar\u0131<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">mRNA tabanl\u0131 tedaviler, DMD dahil olmak \u00fczere genetik hastal\u0131klar\u0131n tedavisinde \u00f6nemli ilerlemeler kaydediyor. mRNA a\u015f\u0131lar\u0131n\u0131n COVID-19 salg\u0131n\u0131yla m\u00fccadeledeki ba\u015far\u0131s\u0131, bu yakla\u015f\u0131ma yeniden dikkat \u00e7ekti ve ara\u015ft\u0131rmac\u0131lar art\u0131k mRNA&#039;n\u0131n DMD&#039;nin temel nedenini ele almak i\u00e7in nas\u0131l kullan\u0131labilece\u011fini ara\u015ft\u0131r\u0131yor. Ama\u00e7, mRNA&#039;y\u0131 kullanarak h\u00fccrelere distrofinin veya kesilmi\u015f formlar\u0131n\u0131n i\u015flevsel versiyonlar\u0131n\u0131 \u00fcretmeleri talimat\u0131n\u0131 vermek ve b\u00f6ylece hastal\u0131\u011f\u0131n ilerlemesini potansiyel olarak durdurmak veya hatta tersine \u00e7evirmektir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">DMD i\u00e7in mRNA tabanl\u0131 tedaviler hala deneysel a\u015famada olsa da, klinik \u00e7al\u0131\u015fmalardan elde edilen erken sonu\u00e7lar cesaret vericidir. Bu tedaviler yaln\u0131zca hastal\u0131\u011f\u0131n ilerlemesini durdurmak i\u00e7in de\u011fil, ayn\u0131 zamanda DMD ile ya\u015fayan bireylerin ya\u015fam kalitesini iyile\u015ftirmek i\u00e7in de umut sunmaktad\u0131r. Ara\u015ft\u0131rmalar devam ettik\u00e7e ve yeni tedaviler geli\u015ftirildik\u00e7e, mRNA, bu zay\u0131flat\u0131c\u0131 hastal\u0131ktan etkilenen ailelere yeni bir yol sunarak DMD bak\u0131m\u0131n\u0131n manzaras\u0131n\u0131 d\u00f6n\u00fc\u015ft\u00fcrmede \u00f6nemli bir rol oynayabilir.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"bobcat-m-rna\">Bobcat mRNA&#039;s\u0131 (Elixirgen Therapeutics)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Son zamanlarda, Elixirgen Therapeutics taraf\u0131ndan olu\u015fturulan tescilli 5&#039;- ve 3&#039;-UTR tasar\u0131m\u0131na sahip bir mRNA olan Bobcat mRNA(TM), tam uzunlukta bir insan distrofin proteini (mRNA-DMD) kodlayan mRNA&#039;y\u0131 ba\u015far\u0131yla \u00fcretmeyi m\u00fcmk\u00fcn k\u0131ld\u0131. \u015eirket, yeti\u015ftirilen insan h\u00fccrelerine mRNA-DMD sokarak, ba\u015flang\u0131\u00e7ta bir insan distrofin proteininin in vitro \u00fcretilebilece\u011fini g\u00f6sterdi. (<a href=\"https:\/\/dmdwarrior.com\/tr\/what-is-bobcat-mrna-how-does-bobcat-mrna-work-for-duchenne-muscular-dystrophy\/\" target=\"_blank\" data-type=\"post\" data-id=\"2506\" rel=\"noreferrer noopener\">Bobcat mRNA<\/a>)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Elixirgen ara\u015ft\u0131rmac\u0131lar\u0131 ayr\u0131ca BALB\/c farelerinin iskelet kaslar\u0131na mRNA-DMD enjekte ederek iskelet kaslar\u0131nda bir insan distrofin proteininin sentezini ve uygun lokalizasyonunu g\u00f6sterdiler. Son olarak, bir kavrama g\u00fcc\u00fc \u00f6l\u00e7er, Duchenne kas distrofisi i\u00e7in bir fare modeli olan D2.mdx mutant farelerinde kas g\u00fcc\u00fcn\u00fcn i\u015flevsel iyile\u015fmesini ikna edici bir \u015fekilde g\u00f6stermek i\u00e7in kullan\u0131ld\u0131.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ara\u015ft\u0131rma ba\u015flang\u0131\u00e7ta, \u00f6n kol kaslar\u0131na alt\u0131 haftal\u0131k mRNA-DMD enjeksiyonunun \u00f6n kolun en y\u00fcksek kas g\u00fcc\u00fcn\u00fc vah\u015fi tip DBA\/2 farelerinin seviyesine geri d\u00f6nd\u00fcrd\u00fc\u011f\u00fcn\u00fc g\u00f6sterdi. Daha sonra, D2.mdx mutant farelerin \u00f6n kol kaslar\u0131na yaln\u0131zca bir mRNA-DMD enjeksiyonundan sonra kas g\u00fc\u00e7lerini geri kazanabileceklerini g\u00f6sterdi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sonu\u00e7lara g\u00f6re, \u00fcretilen DMD proteinleri stabildi ve enjeksiyon b\u00f6lgesinde en az \u00fc\u00e7 hafta kald\u0131. mRNA-DMD enjeksiyonlar\u0131 alan grup i\u00e7in enjeksiyon veya tedaviyle ba\u011flant\u0131l\u0131 herhangi bir g\u00fcvenlik bulgusu yoktu. Duchenne kas distrofisi i\u00e7in mevcut tedavilere potansiyel bir alternatif olarak, bu bulgular lokal ve sonunda sistemik kas terapisi i\u00e7in tam uzunlukta bir insan distrofini kodlayan bir mRNA&#039;n\u0131n iletilmesi olas\u0131l\u0131\u011f\u0131n\u0131 ortaya koymaktad\u0131r. (<a href=\"https:\/\/elixirgentx.com\/#science\" target=\"_blank\" rel=\"noreferrer noopener\">Elixirgen Therapeutics<\/a>)<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"auf-1-expression\">AUF1 mRNA Ba\u011flay\u0131c\u0131 Protein (Regerna Therapeutics)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Son y\u0131llarda kas molek\u00fcler biyolojisinin en ilgi \u00e7ekici y\u00f6nlerinden biri, mRNA translasyonel kontrol\u00fc d\u00fczeyinde kas rejenerasyonunun kontrol\u00fc olmu\u015ftur.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Schneider laboratuvar\u0131nda y\u00fcr\u00fct\u00fclen bir \u00e7al\u0131\u015fman\u0131n odak noktas\u0131, farelerde iskelet kas\u0131n\u0131n korunmas\u0131 i\u00e7in \u00e7ok \u00f6nemli oldu\u011fu g\u00f6sterilen uydu h\u00fccresi mRNA translasyonel kontrol\u00fcn\u00fcn mRNA ba\u011flay\u0131c\u0131 proteinler taraf\u0131ndan nas\u0131l d\u00fczenlendi\u011fini anlamakt\u0131.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Uydu h\u00fccrelerinin kas yenileme yetene\u011fini art\u0131rarak ve fonksiyonel kas geli\u015fimini te\u015fvik ederek, RNA ba\u011flay\u0131c\u0131 protein AU-fakt\u00f6r 1&#039;in (AUF1) kas kayb\u0131n\u0131 durdurdu\u011fu bulundu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Miyofiber b\u00fct\u00fcnl\u00fc\u011f\u00fcn\u00fc, rejenerasyonunu ve mitokondriyal biyogenezisi geri kazand\u0131rmak amac\u0131yla AUF1 gen terapisinin distrofini fonksiyonel olarak ikame edebilece\u011fi ve distrofin homologu olan utrofin \u00fcretimini \u00f6nemli \u00f6l\u00e7\u00fcde art\u0131rabilece\u011fi bulundu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu \u00e7al\u0131\u015fma, Mart 2021&#039;den Eyl\u00fcl 2023&#039;e kadar s\u00fcrecek olan AUF1 takviyesi i\u00e7in ara\u015ft\u0131rma ama\u00e7l\u0131 yeni bir ilac\u0131n geli\u015ftirilmesi amac\u0131yla REGENXBIO ile bir ara\u015ft\u0131rma anla\u015fmas\u0131n\u0131n imzalanmas\u0131na yol a\u00e7t\u0131. REGENXBIO, yakla\u015f\u0131k $2 milyon destek sa\u011flayarak, zay\u0131f kas rejenerasyonunu ve i\u015flevini desteklemede AUF1&#039;in \u00fcst\u00fcnl\u00fc\u011f\u00fcne olan g\u00fcvenini g\u00f6sterdi.<a href=\"https:\/\/regerna.eu\/the-project\" target=\"_blank\" rel=\"noreferrer noopener\">Regerna Therapeutics<\/a>)<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"dmd-anka-m-rna-study-in-turkiye\">DMD ANKA (T\u00fcrkiye&#039;de mRNA \u00c7al\u0131\u015fmas\u0131)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">DMDWarrioR, T\u00fcrkiye&#039;deki ekibe liderlik eden farmakologla ileti\u015fime ge\u00e7ti. Detayl\u0131 bilgileri bizimle payla\u015fan do\u00e7ent, ad\u0131n\u0131n ve \u00fcniversitesinin \u015fimdilik web sitemizde payla\u015f\u0131lmamas\u0131n\u0131 rica etti ve ara\u015ft\u0131rmas\u0131n\u0131n gizlilikle devam etti\u011fini belirtti. &gt;&gt; <a href=\"https:\/\/dmdwarrior.com\/tr\/ali-taghizadeh-announces-dmd-anka-mrna-therapy-currently-in-clinical-trial-in-turkiye\/\" target=\"_blank\" rel=\"noreferrer noopener\">Ali Taghizadeh, T\u00fcrkiye&#039;de Klinik \u00c7al\u0131\u015fma A\u015famas\u0131nda Olan DMD ANKA mRNA Terapisini Duyurdu<\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kendisinden ald\u0131\u011f\u0131m\u0131z bilgiye g\u00f6re Duchenne Musk\u00fcler Distrofi tedavisinde mRNA \u00e7al\u0131\u015fmas\u0131n\u0131n sonu\u00e7lar\u0131 \u00fcmit verici.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Hayvan deneylerinden elde edilen sonu\u00e7lar, tam uzunlukta ve normal distrofin \u00fcretildi\u011fini do\u011frulad\u0131.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00c7ok k\u0131sa bir s\u00fcre i\u00e7erisinde insan deneylerine ba\u015flayabilmek i\u00e7in deneysel s\u00fcre\u00e7lerin sonuna geldiklerini belirtti.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"key-findings-from-m-rna-study-in-turkiye\">T\u00fcrkiye&#039;deki mRNA \u00c7al\u0131\u015fmas\u0131ndan Elde Edilen Temel Bulgular<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>\u00c7al\u0131\u015fmada DNA&#039;ya herhangi bir m\u00fcdahalede bulunulmuyor.<\/li>\n\n\n\n<li>Tam uzunlukta ve normal distrofin \u00fcretimi sa\u011fland\u0131.<\/li>\n\n\n\n<li>BMD ve DMD\u2019li hastalarda uygulanabilir oldu\u011fu d\u00fc\u015f\u00fcn\u00fclmektedir.<\/li>\n\n\n\n<li>Ya\u015fa bak\u0131lmaks\u0131z\u0131n t\u00fcm DMD hastalar\u0131na uygulanabilir.<\/li>\n\n\n\n<li>Yap\u0131lan testlerde herhangi bir olumsuz yan etki g\u00f6r\u00fclmedi.<\/li>\n\n\n\n<li>\u0130lk iki dozun 15 g\u00fcn arayla, di\u011fer dozlar\u0131n ise 6 ayda bir yap\u0131lmas\u0131 planlan\u0131yor.<\/li>\n\n\n\n<li>\u0130kinci denemede de benzer sonu\u00e7lar elde edilirse en k\u0131sa zamanda insan denemelerine ba\u015flanacak.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"conclusion\">Sonu\u00e7<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne Musk\u00fcler Distrofi&#039;de mRNA \u00e7al\u0131\u015fmalar\u0131n\u0131n y\u00fckseli\u015fi, genetik bozukluklar\u0131n gelecekte nas\u0131l tedavi edilebilece\u011fi konusunda d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc bir de\u011fi\u015fimi temsil ediyor. Teknoloji geli\u015fmeye devam ettik\u00e7e ve mRNA uygulamalar\u0131na ili\u015fkin anlay\u0131\u015f\u0131m\u0131z derinle\u015ftik\u00e7e, DMD tedavisinde \u00e7\u0131\u011f\u0131r a\u00e7\u0131c\u0131 geli\u015fmelerin potansiyeli giderek daha somut hale geliyor. Klinik denemelerden ve devam eden ara\u015ft\u0131rmalardan elde edilen erken sonu\u00e7lar, mRNA tabanl\u0131 tedavilerin bu hastal\u0131\u011f\u0131n y\u0131k\u0131c\u0131 etkilerini yava\u015flatman\u0131n veya hatta tersine \u00e7evirmenin anahtar\u0131n\u0131 elinde tutabilece\u011fini \u00f6ne s\u00fcr\u00fcyor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">DMD&#039;den etkilenen aileler ve bireyler i\u00e7in devam eden \u00e7al\u0131\u015fmalar bir umut \u0131\u015f\u0131\u011f\u0131 sunuyor. Hala yap\u0131lacak \u00e7ok i\u015f olsa da, mRNA ara\u015ft\u0131rmalar\u0131ndaki h\u0131zl\u0131 ilerleme h\u0131z\u0131, DMD hastalar\u0131n\u0131n prognozunu \u00f6nemli \u00f6l\u00e7\u00fcde iyile\u015ftirebilecek yeni tedaviler geli\u015ftirme potansiyelinin artt\u0131\u011f\u0131n\u0131 g\u00f6steriyor. mRNA tabanl\u0131 t\u0131p alan\u0131 geli\u015fmeye devam ettik\u00e7e, Duchenne Musk\u00fcler Distrofisi i\u00e7in bir tedavi sa\u011flama hayali bir g\u00fcn ger\u00e7ek olabilir.<\/p>","protected":false},"excerpt":{"rendered":"<p>Given that FDA-approved exon skipping therapies and gene therapy for Duchenne Muscular Dystrophy, which are known to not produce sufficient levels of dystrophin and thus do not completely eliminate Duchenne Muscular Dystrophy (DMD). Over the years, treatment options for DMD have been limited, but a promising area of research has emerged with the use of [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3550,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[183,333,232,186,185,359,202,348,347],"class_list":["post-3537","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-bobcat-mrna","tag-dmd-anka","tag-dmd-treatments","tag-elixirgen","tag-elixirgen-therapeutics","tag-full-length-dystrophin","tag-mrna","tag-regerna","tag-regerna-therapeutics"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/3537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=3537"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/3537\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/3550"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=3537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=3537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=3537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}